Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported
financial results for its first quarter ended June 30, 2023.
“We are pleased with our first quarter results that delivered a
strong start to the year. Solid Q1 revenue and profit growth were
slightly ahead of our expectations, thanks to our leading and
diversified portfolio of brands. Our strategic priority of
disciplined capital deployment remains unchanged, and during Q1 we
completed our share repurchase program while further reducing debt
and leverage,” said Ron Lombardi, Chief Executive Officer of
Prestige Consumer Healthcare.
First Fiscal Quarter Ended June 30, 2023
Reported revenues in the first quarter of fiscal 2024 of $279.3
million increased 0.8% from $277.1 million in the first quarter of
fiscal 2023. Revenues increased 1.8% excluding the impact of
foreign currency. The solid revenue performance for the quarter was
broad-based across North America, partially offset by a slight
decline in the International OTC segments versus the prior year
comparable period.
Reported net income for the first quarter of fiscal 2024 totaled
$53.3 million, compared to the prior year first quarter’s net
income of $55.3 million. Diluted earnings per share of $1.06 for
the first quarter of fiscal 2024 compared to $1.09 in the prior
year comparable period.
Free Cash Flow and Balance Sheet
The Company's net cash provided by operating activities for
first quarter fiscal 2024 was $48.1 million, compared to $58.2
million during the prior year comparable period. Non-GAAP free cash
flow in the first quarter of fiscal 2024 was $46.6 million compared
to $57.2 million in the prior year first quarter, with the change
attributable to the timing of working capital expenditures.
In the first quarter fiscal 2024, the Company repurchased
approximately 0.4 million shares at a total investment of $25.0
million, completing its previously authorized share repurchase
program.
The Company's net debt position as of June 30, 2023 was
approximately $1.3 billion, resulting in a covenant-defined
leverage ratio of 3.2x.
Segment Review
North American OTC Healthcare: Segment revenues of $246.1
million for the first quarter fiscal 2024 increased 1.5% compared
to the prior year comparable quarter's segment revenues of $242.5
million. The revenue performance for the quarter was driven by
strong performance across many brands and led by the Dermatological
and Gastrointestinal categories.
International OTC Healthcare: Fiscal first quarter 2024 revenues
were $33.2 million compared to $34.5 million reported in the prior
year comparable period. The slight decline in revenue versus the
prior year first quarter was driven by a $1.9 million currency
headwind.
Commentary Reaffirming Outlook for Fiscal
2024
Ron Lombardi, Chief Executive Officer, stated, “Our strong start
to fiscal ’24 is fueled by robust growth in multiple categories
such as Dermatological and Gastrointestinal, and highlights the
impact of our long-standing brand-building across our diverse
portfolio. Meanwhile, we continued to generate strong profitability
and free cash flow that allowed us to reduce our leverage to 3.2x
at the end of Q1, even with our $25 million share repurchase that
drove additional shareholder value.”
“We are reaffirming our fiscal 2024 outlook that includes solid
sales and earnings growth that builds off our record fiscal 2023
performance. We remain focused on executing our proven business
strategy and leveraging our diverse portfolio of brands to create
shareholder value,” Mr. Lombardi concluded.
|
Reaffirmed Fiscal 2024 Outlook |
Revenue |
$1,135 to $1,140 million |
Organic Revenue Growth |
1% to 2% |
Diluted E.P.S. |
$4.27 to $4.32 |
Free Cash Flow |
$240 million or more |
|
|
Fiscal First Quarter 2024 Conference Call, Accompanying
Slide Presentation and Replay
The Company will host a conference call to review its first
quarter fiscal 2024 results today, August 3, 2023 at 8:30 a.m. ET.
The Company provides a live Internet webcast, a slide presentation
to accompany the call, as well as an archived replay, all of which
can be accessed from the Investor Relations page of the Company's
website at www.prestigeconsumerhealthcare.com. To participate in
the conference call via phone, participants may register for the
call here to receive dial-in details and a unique pin.
While not required, it is recommended to join 10 minutes prior to
the event start. The slide presentation can be accessed from the
Investor Relations page of the website by clicking on Webcasts and
Presentations.
A conference call replay will be available for approximately one
week following completion of the live call and can be accessed on
the Company’s Investor Relations page.
Non-GAAP and Other Financial Information
In addition to financial results reported in accordance with
generally accepted accounting principles (GAAP), we have provided
certain non-GAAP financial information in this release to aid
investors in understanding the Company's performance. Each non-GAAP
financial measure is defined and reconciled to its most closely
related GAAP financial measure in the “About Non-GAAP Financial
Measures” section at the end of this earnings release.
Note Regarding Forward-Looking Statements
This news release contains "forward-looking statements" within
the meaning of the federal securities laws that are intended to
qualify for the Safe Harbor from liability established by the
Private Securities Litigation Reform Act of 1995. "Forward-looking
statements" generally can be identified by the use of
forward-looking terminology such as "guidance," "outlook,"
"projected," “focus,” “priority,” "may," "will," "would," "expect,"
"anticipate," "believe,” or "continue" (or the negative or other
derivatives of each of these terms) or similar terminology. The
"forward-looking statements" include, without limitation,
statements regarding the Company's future operating results
including revenues, organic growth, diluted earnings per share, and
free cash flow, the Company’s priority of disciplined capital
deployment, and the Company’s ability to create shareholder value.
These statements are based on management's estimates and
assumptions with respect to future events and financial performance
and are believed to be reasonable, though are inherently uncertain
and difficult to predict. Actual results could differ materially
from those expected as a result of a variety of factors, including
the impact of business and economic conditions, including as a
result of labor shortages, inflation and geopolitical instability,
consumer trends, the impact of the Company’s advertising and
marketing and new product development initiatives, customer
inventory management initiatives, fluctuating foreign exchange
rates, competitive pressures, and the ability of the Company’s
manufacturing operations and third party manufacturers and
logistics providers and suppliers to meet demand for its products
and to avoid inflationary cost increases and disruption as a result
of labor shortages. A discussion of other factors that could cause
results to vary is included in the Company's Annual Report on Form
10-K for the year ended March 31, 2023 and other periodic reports
filed with the Securities and Exchange Commission.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare is a leading consumer healthcare
products company with sales throughout the U.S. and Canada,
Australia, and in certain other international markets. The
Company’s diverse portfolio of brands include Monistat® and
Summer’s Eve® women's health products, BC® and Goody's® pain
relievers, Clear Eyes® and TheraTears® eye care products, DenTek®
specialty oral care products, Dramamine® motion sickness
treatments, Fleet® enemas and glycerin suppositories, Chloraseptic®
and Luden's® sore throat treatments and drops, Compound W® wart
treatments, Little Remedies® pediatric over-the-counter products,
Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment,
Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte®
rehydration products and the Fess® line of nasal and sinus care
products in Australia. Visit the Company's website at
www.prestigeconsumerhealthcare.com.
Prestige Consumer Healthcare
Inc.Condensed Consolidated Statements of Income
and Comprehensive Income (Unaudited)
|
Three Months Ended June 30, |
(In thousands, except
per share data) |
|
2023 |
|
|
|
2022 |
|
Total
Revenues |
$ |
279,309 |
|
|
$ |
277,059 |
|
|
|
|
|
Cost of
Sales |
|
|
|
Cost of sales excluding depreciation |
|
122,654 |
|
|
|
114,996 |
|
Cost of sales depreciation |
|
1,982 |
|
|
|
1,944 |
|
Cost of sales |
|
124,636 |
|
|
|
116,940 |
|
Gross profit |
|
154,673 |
|
|
|
160,119 |
|
|
|
|
|
Operating
Expenses |
|
|
|
Advertising and marketing |
|
36,231 |
|
|
|
39,951 |
|
General and administrative |
|
27,687 |
|
|
|
26,714 |
|
Depreciation and amortization |
|
5,561 |
|
|
|
6,440 |
|
Total operating expenses |
|
69,479 |
|
|
|
73,105 |
|
Operating income |
|
85,194 |
|
|
|
87,014 |
|
|
|
|
|
Other
expense |
|
|
|
Interest expense, net |
|
17,719 |
|
|
|
15,292 |
|
Other (income) expense, net |
|
(1,238 |
) |
|
|
825 |
|
Total other expense, net |
|
16,481 |
|
|
|
16,117 |
|
Income before income taxes |
|
68,713 |
|
|
|
70,897 |
|
Provision for income taxes |
|
15,437 |
|
|
|
15,625 |
|
Net income |
$ |
53,276 |
|
|
$ |
55,272 |
|
|
|
|
|
Earnings per share: |
|
|
|
Basic |
$ |
1.07 |
|
|
$ |
1.10 |
|
Diluted |
$ |
1.06 |
|
|
$ |
1.09 |
|
|
|
|
|
Weighted average shares
outstanding: |
|
|
|
Basic |
|
49,767 |
|
|
|
50,264 |
|
Diluted |
|
50,196 |
|
|
|
50,730 |
|
|
|
|
|
Comprehensive income, net of
tax: |
|
|
|
Currency translation adjustments |
|
(646 |
) |
|
|
(9,519 |
) |
Net loss on termination of pension plan |
|
— |
|
|
|
(790 |
) |
Total other comprehensive
loss |
|
(646 |
) |
|
|
(10,309 |
) |
Comprehensive income |
$ |
52,630 |
|
|
$ |
44,963 |
|
Prestige Consumer Healthcare
Inc.Condensed Consolidated Balance
Sheets(Unaudited)
(In
thousands) |
June 30, 2023 |
|
March 31, 2023 |
|
|
|
|
Assets |
|
|
|
Current assets |
|
|
|
Cash and cash equivalents |
$ |
54,580 |
|
$ |
58,489 |
Accounts receivable, net of
allowance of $24,928 and $20,205, respectively |
|
157,950 |
|
|
167,016 |
Inventories |
|
169,849 |
|
|
162,121 |
Prepaid expenses and other current assets |
|
9,379 |
|
|
4,117 |
Total current assets |
|
391,758 |
|
|
391,743 |
|
|
|
|
Property, plant and equipment,
net |
|
69,979 |
|
|
70,412 |
Operating lease right-of-use
assets |
|
13,443 |
|
|
14,923 |
Finance lease right-of-use
assets, net |
|
3,535 |
|
|
4,200 |
Goodwill |
|
527,458 |
|
|
527,553 |
Intangible assets, net |
|
2,336,137 |
|
|
2,341,893 |
Other long-term assets |
|
3,267 |
|
|
3,005 |
Total Assets |
$ |
3,345,577 |
|
$ |
3,353,729 |
|
|
|
|
Liabilities and
Stockholders' Equity |
|
|
|
Current liabilities |
|
|
|
Accounts payable |
|
57,861 |
|
|
62,743 |
Accrued interest payable |
|
15,188 |
|
|
15,688 |
Operating lease liabilities, current portion |
|
6,600 |
|
|
6,926 |
Finance lease liabilities, current portion |
|
2,855 |
|
|
2,834 |
Other accrued liabilities |
|
64,767 |
|
|
72,524 |
Total current liabilities |
|
147,271 |
|
|
160,715 |
|
|
|
|
Long-term debt, net |
|
1,316,711 |
|
|
1,345,788 |
Deferred income tax
liabilities |
|
383,955 |
|
|
380,434 |
Long-term operating lease
liabilities, net of current portion |
|
8,217 |
|
|
9,876 |
Long-term finance lease
liabilities, net of current portion |
|
945 |
|
|
1,667 |
Other long-term
liabilities |
|
8,183 |
|
|
8,165 |
Total Liabilities |
|
1,865,282 |
|
|
1,906,645 |
|
|
|
|
Total Stockholders'
Equity |
|
1,480,295 |
|
|
1,447,084 |
Total Liabilities and
Stockholders' Equity |
$ |
3,345,577 |
|
$ |
3,353,729 |
Prestige Consumer Healthcare
Inc.Condensed Consolidated Statements of Cash
Flows(Unaudited)
|
Three Months Ended June 30, |
(In
thousands) |
|
2023 |
|
|
|
2022 |
|
Operating
Activities |
|
|
|
Net income |
$ |
53,276 |
|
|
$ |
55,272 |
|
Adjustments to reconcile net
income to net cash provided by operating activities: |
|
|
|
Depreciation and amortization |
|
7,543 |
|
|
|
8,384 |
|
Loss on disposal of property and equipment |
|
— |
|
|
|
13 |
|
Deferred income taxes |
|
4,272 |
|
|
|
1,213 |
|
Amortization of debt origination costs |
|
983 |
|
|
|
828 |
|
Stock-based compensation costs |
|
4,146 |
|
|
|
3,857 |
|
Non-cash operating lease cost |
|
1,244 |
|
|
|
1,493 |
|
Other |
|
— |
|
|
|
446 |
|
Changes in operating assets
and liabilities: |
|
|
|
Accounts receivable |
|
5,632 |
|
|
|
(7,079 |
) |
Inventories |
|
(7,711 |
) |
|
|
(14,415 |
) |
Prepaid expenses and other current assets |
|
(5,181 |
) |
|
|
(3,227 |
) |
Accounts payable |
|
(5,599 |
) |
|
|
2,542 |
|
Accrued liabilities |
|
(8,519 |
) |
|
|
10,524 |
|
Operating lease liabilities |
|
(1,745 |
) |
|
|
(1,602 |
) |
Other |
|
(254 |
) |
|
|
(2 |
) |
Net cash provided by operating activities |
|
48,087 |
|
|
|
58,247 |
|
|
|
|
|
Investing
Activities |
|
|
|
Purchases of property, plant
and equipment |
|
(1,477 |
) |
|
|
(1,047 |
) |
Other |
|
3,800 |
|
|
|
— |
|
Net cash provided by (used in) investing activities |
|
2,323 |
|
|
|
(1,047 |
) |
|
|
|
|
Financing
Activities |
|
|
|
Term loan repayments |
|
(30,000 |
) |
|
|
(15,000 |
) |
Borrowings under revolving
credit agreement |
|
— |
|
|
|
20,000 |
|
Repayments under revolving
credit agreement |
|
— |
|
|
|
(10,000 |
) |
Payments of finance
leases |
|
(699 |
) |
|
|
(686 |
) |
Proceeds from exercise of
stock options |
|
7,028 |
|
|
|
1,489 |
|
Fair value of shares
surrendered as payment of tax withholding |
|
(5,508 |
) |
|
|
(5,450 |
) |
Repurchase of common
stock |
|
(25,000 |
) |
|
|
(37,727 |
) |
Net cash used in financing activities |
|
(54,179 |
) |
|
|
(47,374 |
) |
|
|
|
|
Effects of exchange rate
changes on cash and cash equivalents |
|
(140 |
) |
|
|
(1,142 |
) |
Increase (decrease) in cash
and cash equivalents |
|
(3,909 |
) |
|
|
8,684 |
|
Cash and cash equivalents -
beginning of period |
|
58,489 |
|
|
|
27,185 |
|
Cash and cash equivalents -
end of period |
$ |
54,580 |
|
|
$ |
35,869 |
|
Interest paid |
$ |
17,582 |
|
|
$ |
3,562 |
|
Income taxes paid |
$ |
11,964 |
|
|
$ |
1,799 |
|
Prestige Consumer Healthcare
Inc.Condensed Consolidated Statements of
IncomeBusiness
Segments(Unaudited)
|
Three Months Ended June 30, 2023 |
(In
thousands) |
North American OTC Healthcare |
|
International OTC Healthcare |
|
Consolidated |
Total segment revenues* |
$ |
246,143 |
|
$ |
33,166 |
|
$ |
279,309 |
Cost of sales |
|
110,076 |
|
|
14,560 |
|
|
124,636 |
Gross profit |
|
136,067 |
|
|
18,606 |
|
|
154,673 |
Advertising and marketing |
|
31,401 |
|
|
4,830 |
|
|
36,231 |
Contribution margin |
$ |
104,666 |
|
$ |
13,776 |
|
$ |
118,442 |
Other operating expenses |
|
|
|
|
|
33,248 |
Operating income |
|
|
|
|
$ |
85,194 |
*Intersegment revenues of $1.4 million were eliminated from the
North American OTC Healthcare segment.
|
Three Months Ended June 30, 2022 |
(In
thousands) |
North American OTC Healthcare |
|
International OTC Healthcare |
|
Consolidated |
Total segment revenues* |
$ |
242,518 |
|
$ |
34,541 |
|
$ |
277,059 |
Cost of sales |
|
102,921 |
|
|
14,019 |
|
|
116,940 |
Gross profit |
|
139,597 |
|
|
20,522 |
|
|
160,119 |
Advertising and marketing |
|
35,412 |
|
|
4,539 |
|
|
39,951 |
Contribution margin |
$ |
104,185 |
|
$ |
15,983 |
|
$ |
120,168 |
Other operating expenses |
|
|
|
|
|
33,154 |
Operating income |
|
|
|
|
$ |
87,014 |
* Intersegment revenues of $0.5 million were
eliminated from the North American OTC Healthcare segment.
About Non-GAAP Financial Measures
In addition to financial results reported in
accordance with GAAP, we disclose certain Non-GAAP financial
measures ("NGFMs"), including, but not limited to, Non-GAAP Organic
Revenues, Non-GAAP Organic Revenue Change Percentage, Non-GAAP
EBITDA, Non-GAAP EBITDA Margin, Non-GAAP Free Cash Flow, and Net
Debt.
We use these NGFMs internally, along with GAAP
information, in evaluating our operating performance and in making
financial and operational decisions. We believe that the
presentation of these NGFMs provides investors with greater
transparency, and provides a more complete understanding of our
business than could be obtained absent these disclosures, because
the supplemental data relating to our financial condition and
results of operations provides additional ways to view our
operation when considered with both our GAAP results and the
reconciliations below. In addition, we believe that the
presentation of each of these NGFMs is useful to investors for
period-to-period comparisons of results in assessing shareholder
value, and we use these NGFMs internally to evaluate the
performance of our personnel and also to evaluate our operating
performance and compare our performance to that of our
competitors.
These NGFMs are not in accordance with GAAP,
should not be considered as a measure of profitability or
liquidity, and may not be directly comparable to similarly titled
NGFMs reported by other companies. These NGFMs have limitations and
they should not be considered in isolation from or as an
alternative to their most closely related GAAP measures reconciled
below. Investors should not rely on any single financial measure
when evaluating our business. We recommend investors review the
GAAP financial measures included in this earnings release. When
viewed in conjunction with our GAAP results and the reconciliations
below, we believe these NGFMs provide greater transparency and a
more complete understanding of factors affecting our business than
GAAP measures alone.
NGFMs Defined
We define our NGFMs presented herein as
follows:
- Non-GAAP Organic Revenues: GAAP
Total Revenues excluding the impact of foreign currency exchange
rates in the periods presented.
- Non-GAAP Organic Revenue Change
Percentage: Calculated as the change in Non-GAAP Organic Revenues
from prior year divided by prior year Non-GAAP Organic
Revenues.
- Non-GAAP EBITDA: GAAP Net Income
before interest expense, net, provision for income taxes, and
depreciation and amortization.
- Non-GAAP EBITDA Margin: Calculated
as Non-GAAP EBITDA divided by GAAP Total Revenues.
- Non-GAAP Free Cash Flow: Calculated
as GAAP Net cash provided by operating activities less cash paid
for capital expenditures.
- Net Debt: Calculated as total
principal amount of debt outstanding ($1,330,000 at June 30,
2023) less cash and cash equivalents ($54,580 at June 30,
2023). Amounts in thousands.
The following tables set forth the
reconciliations of each of our NGFMs (other than Net Debt, which is
reconciled above) to their most directly comparable financial
measures presented in accordance with GAAP.
Reconciliation of GAAP Total Revenues to Non-GAAP
Organic Revenues and related Non-GAAP Organic Revenue Change
percentage:
|
|
Three Months Ended June 30, |
|
|
|
2023 |
|
|
|
2022 |
|
(In
thousands) |
|
|
|
|
GAAP Total Revenues |
|
$ |
279,309 |
|
|
$ |
277,059 |
|
Revenue Change |
|
|
0.8 |
% |
|
|
Adjustments: |
|
|
|
|
Impact of foreign currency
exchange rates |
|
|
— |
|
|
|
(2,724 |
) |
Total adjustments |
|
|
— |
|
|
|
(2,724 |
) |
Non-GAAP Organic Revenues |
|
$ |
279,309 |
|
|
$ |
274,335 |
|
Non-GAAP Organic Revenue
Change |
|
|
1.8 |
% |
|
|
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and
related Non-GAAP EBITDA Margin:
|
Three Months Ended June 30, |
|
|
2023 |
|
|
|
2022 |
|
(In
thousands) |
|
|
|
GAAP Net Income |
$ |
53,276 |
|
|
$ |
55,272 |
|
Interest expense, net |
|
17,719 |
|
|
|
15,292 |
|
Provision for income
taxes |
|
15,437 |
|
|
|
15,625 |
|
Depreciation and
amortization |
|
7,543 |
|
|
|
8,384 |
|
Non-GAAP EBITDA |
$ |
93,975 |
|
|
$ |
94,573 |
|
Non-GAAP EBITDA Margin |
|
33.6 |
% |
|
|
34.1 |
% |
Reconciliation of GAAP Net Income to Non-GAAP Free Cash
Flow:
|
Three Months Ended June 30, |
|
|
2023 |
|
|
|
2022 |
|
(In
thousands) |
|
|
|
GAAP Net Income |
$ |
53,276 |
|
|
$ |
55,272 |
|
Adjustments: |
|
|
|
Adjustments to reconcile net
income to net cash provided by operating activities as shown in the
Statement of Cash Flows |
|
18,188 |
|
|
|
16,234 |
|
Changes in operating assets
and liabilities as shown in the Statement of Cash Flows |
|
(23,377 |
) |
|
|
(13,259 |
) |
Total adjustments |
|
(5,189 |
) |
|
|
2,975 |
|
GAAP Net cash provided by
operating activities |
|
48,087 |
|
|
|
58,247 |
|
Purchases of property and
equipment |
|
(1,477 |
) |
|
|
(1,047 |
) |
Non-GAAP Free Cash Flow |
$ |
46,610 |
|
|
$ |
57,200 |
|
Outlook for Fiscal Year
2024:
Reconciliation of Projected GAAP Net
cash provided by operating activities to Projected Non-GAAP Free
Cash Flow:
(In
millions) |
|
|
Projected FY'24 GAAP Net cash
provided by operating activities |
|
$ |
250 |
|
Additions to property and
equipment for cash |
|
|
(10 |
) |
Projected FY'24 Non-GAAP Free
Cash Flow |
|
$ |
240 |
|
Prestige Consumer Health... (NYSE:PBH)
Historical Stock Chart
From Apr 2024 to May 2024
Prestige Consumer Health... (NYSE:PBH)
Historical Stock Chart
From May 2023 to May 2024